Linked Life Data

20064707

Source:http://linkedlifedata.com/resource/pubmed/id/20064707

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20064707rdf:typepubmed:Citationlld:pubmed
pubmed-article:20064707lifeskim:mentionsumls-concept:C0024299lld:lifeskim
pubmed-article:20064707lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:20064707lifeskim:mentionsumls-concept:C0078058lld:lifeskim
pubmed-article:20064707lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:20064707lifeskim:mentionsumls-concept:C0033414lld:lifeskim
pubmed-article:20064707lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:20064707lifeskim:mentionsumls-concept:C1366753lld:lifeskim
pubmed-article:20064707lifeskim:mentionsumls-concept:C1332737lld:lifeskim
pubmed-article:20064707lifeskim:mentionsumls-concept:C0597170lld:lifeskim
pubmed-article:20064707lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:20064707lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:20064707lifeskim:mentionsumls-concept:C0441712lld:lifeskim
pubmed-article:20064707pubmed:issue5lld:pubmed
pubmed-article:20064707pubmed:dateCreated2010-3-8lld:pubmed
pubmed-article:20064707pubmed:abstractTextIncreased levels of circulating VEGF-A have been demonstrated in patients with non-Hodgkin lymphoma (NHL) and are associated with progressive disease and poor clinical outcome. We investigated the role of VEGF-A in lymphoma tumour growth on a molecular level in order to identify the mechanism of VEGF-A-promoted tumour growth and to identify the potential targets for therapy. We used a model in which Daudi (human Burkitt lymphoma) tumour cells were transduced with VEGF-A165 or an empty vector (negative control) and subcutaneously injected in NOD/SCID mice. The weight of tumours overexpressing VEGF-A was increased 4-fold compared to that of control tumours (p<0.0001), whereas no in vitro growth advantage was demonstrated upon VEGF-A overexpression. VEGF-A-tumours were associated with increased microvessel densities (p=0.004) and increased tumour cell proliferation (Ki67; p<0.001) compared to control tumours. VEGF-A-tumours were characterised by upregulation of phosphorylated STAT-4 and STAT-6 and downregulation of phospho-p27(KIP1), a crucial cell cycle inhibitor (p<0.05). This was accompanied by increased levels of phosphorylated receptor tyrosine kinases, including EGFR (ErbB-2 and ErbB-4, p<0.05), an upstream regulator of STAT proteins. We demonstrated that various mouse-derived cytokines produced by mouse-derived tumour stromal cells are upregulated in VEGF-A-tumours compared to control tumours (p<0.05). These results indicate an important role for the tumour microenvironment in paracrine promotion of lymphoma tumour growth in response to tumour-derived VEGF-A. In conclusion, lymphoma-derived VEGF-A promoted lymphoma tumour growth in a paracrine loop by activation of tumour stromal cells. Our study reveals VEGF-A and STAT proteins as potential additional targets in the treatment of lymphoma.lld:pubmed
pubmed-article:20064707pubmed:languageenglld:pubmed
pubmed-article:20064707pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20064707pubmed:citationSubsetIMlld:pubmed
pubmed-article:20064707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20064707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20064707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20064707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20064707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20064707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20064707pubmed:statusMEDLINElld:pubmed
pubmed-article:20064707pubmed:monthMarlld:pubmed
pubmed-article:20064707pubmed:issn1879-0852lld:pubmed
pubmed-article:20064707pubmed:authorpubmed-author:KampsWillem...lld:pubmed
pubmed-article:20064707pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:20064707pubmed:authorpubmed-author:RoordaBerber...lld:pubmed
pubmed-article:20064707pubmed:authorpubmed-author:Ter ElstArjaAlld:pubmed
pubmed-article:20064707pubmed:authorpubmed-author:ScherpenFrank...lld:pubmed
pubmed-article:20064707pubmed:authorpubmed-author:Meeuwsen-de...lld:pubmed
pubmed-article:20064707pubmed:copyrightInfoCopyright 2009 Elsevier Ltd. All rights reserved.lld:pubmed
pubmed-article:20064707pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20064707pubmed:volume46lld:pubmed
pubmed-article:20064707pubmed:ownerNLMlld:pubmed
pubmed-article:20064707pubmed:authorsCompleteYlld:pubmed
pubmed-article:20064707pubmed:pagination974-82lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:meshHeadingpubmed-meshheading:20064707...lld:pubmed
pubmed-article:20064707pubmed:year2010lld:pubmed
pubmed-article:20064707pubmed:articleTitleVEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms.lld:pubmed
pubmed-article:20064707pubmed:affiliationDivision of Pediatric Oncology/Hematology, Department of Pediatrics, University Medical Center Groningen, University of Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.lld:pubmed
pubmed-article:20064707pubmed:publicationTypeJournal Articlelld:pubmed